Syros Pharmaceuticals Stock Investor Sentiment

SYRS Stock  USD 0.16  0.01  5.88%   
Slightly above 68% of Syros Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Syros Pharmaceuticals suggests that many traders are alarmed. Syros Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Syros Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  

Syros Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Syros Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at investing.com         
Syros Pharmaceuticals chief legal officer sells 10,320 in stock
Investing News at Macroaxis
over three months ago at www.macroaxis.com         
Disposition of 46657 shares by Quirk Gerald E of Syros Pharmaceuticals at 0.2212 subject to Rule 16b...
Macroaxis News
over three months ago at investing.com         
Syros Pharmaceuticals announces major company changes
Investing News at Macroaxis
over three months ago at investing.com         
Disposition of 137803 shares by Jason Haas of Syros Pharmaceuticals at 0.2103 subject to Rule 16b-3
Investing News at Macroaxis
over three months ago at thelincolnianonline.com         
Syros Pharmaceuticals Given Neutral Rating at HC Wainwright
news
over three months ago at gurufocus.com         
Avidity Partners Management LPs Strategic Acquisition in Syros Pharmaceuticals Inc
Gurufocus Stories at Macroaxis
over three months ago at finance.yahoo.com         
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
Yahoo News
over three months ago at bizjournals.com         
Petri Dish Syros stock plunges 85 percent on trial fail New CEOs at Flagship spinouts
bizjournals News
over three months ago at benzinga.com         
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
benzinga news
over three months ago at investing.com         
Syros Pharmaceuticals SWOT analysis stock faces headwinds after trial setback
Investing News at Macroaxis
over three months ago at seekingalpha.com         
Syros cut to neutral by H.C. Wainwright on failed drug study
seekingalpha News
over three months ago at investing.com         
JMP Securities cuts Syros Pharma stock to Market Perform
Investing News at Macroaxis
over three months ago at investing.com         
TD Cowen downgrades Syros Pharma stock to Hold on trial failure
Investing News at Macroaxis
over three months ago at finance.yahoo.com         
Syros stock craters after lead cancer therapy flops in Phase III trial
Yahoo News
over three months ago at investing.com         
JMP Securities cuts Syros Pharma stock rating following unsuccessful trial
Investing News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Syros Pharmaceuticals that are available to investors today. That information is available publicly through Syros media outlets and privately through word of mouth or via Syros internal channels. However, regardless of the origin, that massive amount of Syros data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Syros Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Syros Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Syros Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Syros Pharmaceuticals alpha.

Syros Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 134713 shares by Simonian Nancy A of Syros Pharmaceuticals at 0.2653 subject to Rule 16b-3
11/25/2024
2
Disposition of 37070 shares by Simonian Nancy A of Syros Pharmaceuticals at 0.2702 subject to Rule 16b-3
12/02/2024
3
Acquisition by Richard Young of 2667 shares of Syros Pharmaceuticals subject to Rule 16b-3
12/06/2024
4
Kia Syros Is A Sub-4m SUV With Quirky Styling And Generous Equipment
12/19/2024
5
BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President
01/06/2025
6
Syros Pharmaceuticals stock hits 52-week low at 0.18 amid steep decline - MSN
01/29/2025
7
ADAGE CAPITAL PARTNERS GP, L.L.C. Reduces Stake in Syros Pharmaceuticals Inc
02/12/2025
8
Syros Pharmaceuticals, Inc. Given Consensus Recommendation of Hold by Brokerages
02/21/2025

Additional Tools for Syros Stock Analysis

When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.